奥马珠单抗治疗儿童过敏性疾病的临床研究

Clinical research of Omalizumab in treatment of children with allergic diseases

目的探讨奥马珠单抗在患多种过敏性疾病儿童中的治疗效果。方法回顾性分析2020年9月至2022年9月就诊于南京医科大学附属明基医院儿科过敏性疾病门诊并使用奥马珠单抗治疗患儿的临床资料, 分析患儿性别、年龄、过敏性疾病的种类、血清总IgE(TIgE)、皮肤点刺试验结果和(或)血清过敏原特异性IgE(sIgE)水平、奥马珠单抗治疗剂量、治疗效果及药物不良反应情况。结果接受奥马珠单抗治疗的43例患儿, 男/女为24/19;年龄(9.3±2.5)岁。患过敏性疾病种类:支气管哮喘43例(100%), 变应性鼻炎43例(100%), 过敏性结膜炎5例(11.6%), 特应性皮炎18例(41.9%), 牛奶蛋白过敏1例(2.3%)。43例患儿血清TIgE[(613.27±616.21)Ku/L]均明显升高。所有患儿过敏原检测均为阳性, 其中尘螨过敏占比最高(93%)。治疗后43例哮喘合并变应性鼻炎患儿喘息发作次数减少, 鼻炎症状明显减轻;5例过敏性结膜炎患儿眼红、眼痒症状均明显改善;特应性皮炎患儿17例皮肤瘙痒减轻, 1例改善不佳;1例牛奶过敏患儿可耐受奶制品。结论奥马珠单抗对同时存在多种过敏性疾病的患儿有明显治疗效果。

Objective To investigate the therapeutic effect of Omalizumab in children suffering from multiple allergic diseases.Methods The clinical data of children treated with Omalizumab in the Affiliated BenQ Hospital of Nanjing Medical University from September 2020 to September 2022 were retrospectively analyzed.Their gender,age,type of allergic disease,serum total IgE(TIgE),skin prick test and/or serum allergen specific IgE(sIgE)levels,Omalizumab dosage,therapeutic effect and adverse drug reactions were analyzed.Results Forty-three children(male/female,24/19)were treated with Omalizumab.The age is(9.3±2.5)years.Types of allergic diseases:43 cases of asthma(100%),43 cases of allergic rhinitis(100%),5 cases of allergic conjunctivitis(11.6%),18 cases of atopic dermatitis(41.9%),1 case of milk protein allergy(2.3%).All the 43 patients had elevated TIgE[(613.27±616.21)Ku/L].Allergen testing for all the children were positive,with dust mite allergy accounting for the highest proportion(93%).After treatment,the frequency of wheezing attacks was reduced and the nasal symptoms were alleviate in 43 children with asthma combined with allergic rhinitis;5 children with allergic conjunctivitis had significantly improved symptoms of redness and itching;the skin itching in 17 children with atopic dermatitis was alleviated,and 1case had poor improvement;1 child with milk allergy could tolerate dairy products.Conclusion There are significant therapeutic benefits of Omalizumab in children with multiple allergic diseases.